TABLE 1.
Patient characteristics
| Demographic/disease characteristic | N = 28 n (%) |
|---|---|
| Age (years), Median (range) | 64.0 (43–79) |
| Disease site | |
| Ovary | 21 (75%) |
| Fallopian tube | 6 (21%) |
| Primary peritoneal | 1 (4%) |
| Histology | |
| High-grade serous carcinoma | 28 (100%) |
| ECOG | |
| 0 | 13 (46%) |
| 1 | 15 (54%) |
| p53 status | |
| Molecular mutation | 24 (86%) |
| IHC | 6 negative (21%) 13 positive (46%) 9 NA (32%) |
| BRCA status | |
| Molecular mutation | 2 positive (7%) 13 negative (46%) 13 NA (46%) |
| Prior treatment, Median (range) | |
| Total drug regimens | 4 (2–7) |
| Total drug regimens for recurrent/refractory disease | 2 (1–4) |
| Chemotherapy regimens recurrent/refractory disease | 2 (1–4) |
| Prior PARP inhibitor | 12 (43%) |
| Prior bevacizumab | 20 (71%) |